DE06025470T1 - Reinigung von Polysaccharid-Protein-Konjugat Impfstoffen durch Ultrafiltration mit Ammoniumsulfat-Lösungen - Google Patents

Reinigung von Polysaccharid-Protein-Konjugat Impfstoffen durch Ultrafiltration mit Ammoniumsulfat-Lösungen Download PDF

Info

Publication number
DE06025470T1
DE06025470T1 DE06025470T DE06025470T DE06025470T1 DE 06025470 T1 DE06025470 T1 DE 06025470T1 DE 06025470 T DE06025470 T DE 06025470T DE 06025470 T DE06025470 T DE 06025470T DE 06025470 T1 DE06025470 T1 DE 06025470T1
Authority
DE
Germany
Prior art keywords
polysaccharide
protein
ammonium sulfate
mixture
membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE06025470T
Other languages
English (en)
Inventor
Ronald P. Stroudsburg McMaster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Sanofi Pasteur Inc
Original Assignee
Connaught Laboratories Ltd
Connaught Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Laboratories Ltd, Connaught Laboratories Inc filed Critical Connaught Laboratories Ltd
Publication of DE06025470T1 publication Critical patent/DE06025470T1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Verfahren zur Entfernung von ungebundenem Polysaccharid von Protein-Polysaccharid-Konjugat-Vakzinen in einem Gemisch von Protein-Polysaccharid-Konjugat und ungebundenem Polysaccharid, wobei das Verfahren ein Zusetzen von sättigenden Mengen an Ammoniumsulfat zu dem Gemisch umfasst, gefolgt von Filtration des Gemisches durch eine semipermeable Membran.

Claims (12)

  1. Verfahren zur Entfernung von ungebundenem Polysaccharid von Protein-Polysaccharid-Konjugat-Vakzinen in einem Gemisch von Protein-Polysaccharid-Konjugat und ungebundenem Polysaccharid, wobei das Verfahren ein Zusetzen von sättigenden Mengen an Ammoniumsulfat zu dem Gemisch umfasst, gefolgt von Filtration des Gemisches durch eine semipermeable Membran.
  2. Verfahren nach Anspruch 1, wobei die semipermeable Membran hydrophob ist.
  3. Verfahren nach Anspruch 2, wobei die hydrophobe Membran aus Polyethersulfon zusammengesetzt ist.
  4. Verfahren nach Anspruch 3, wobei die Polyethersulfonmembran einen Molekulargewichtsausschluss von 30.000 aufweist.
  5. Verfahren nach Anspruch 1, wobei die semipermeable Membran hydrophil ist.
  6. Verfahren nach Anspruch 5, wobei die hydrophile Membran aus regenerierter Zellulose zusammengesetzt ist.
  7. Verfahren nach Anspruch 6, wobei die regenerierte Zellulose einen Molekulargewichtsausschluss von 30.000 aufweist.
  8. Verfahren nach Anspruch 1, wobei das Ammoniumsulfat bei 20 bis 60% Sättigung vorhanden ist.
  9. Verfahren nach Anspruch 1, wobei das Protein Diphtherietoxoid ist.
  10. Verfahren nach Anspruch 1, wobei das Polysaccharid kapsuläres Polysaccharid aus Bakterien ist, ausgewählt aus der Gruppe bestehend aus Streptococcus pneumoniae-Serotypen 1, 3, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F und Neisseria meningitidis-Serogruppen A, C, W-135 und Y.
  11. Aufgereinigte Polysaccharid-Protein-Konjugat-Vakzine, hergestellt durch das Verfahren gemäß einem der Ansprüche 1 bis 10.
  12. Aufgereinigte Polysaccharid-Protein-Konjugat-Vakzine gemäß Anspruch 11, die weniger als 1% an ungebundenem Polysaccharid nach Gewicht enthält.
DE06025470T 1998-12-29 1999-12-16 Reinigung von Polysaccharid-Protein-Konjugat Impfstoffen durch Ultrafiltration mit Ammoniumsulfat-Lösungen Pending DE06025470T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US221728 1994-04-01
US09/221,728 US6146902A (en) 1998-12-29 1998-12-29 Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions

Publications (1)

Publication Number Publication Date
DE06025470T1 true DE06025470T1 (de) 2007-08-02

Family

ID=22829099

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69934434T Expired - Lifetime DE69934434T2 (de) 1998-12-29 1999-12-16 Reinigung von polysaccharid-protein-konjugat impfstoffen durch ultrafiltration mit ammoniumsulfat-lösungen
DE69943169T Expired - Lifetime DE69943169D1 (de) 1998-12-29 1999-12-16 Reinigung von Polysaccharid-Protein-Konjugat Impfstoffen durch Ultrafiltration mit Ammoniumsulfat-Lösungen
DE06025470T Pending DE06025470T1 (de) 1998-12-29 1999-12-16 Reinigung von Polysaccharid-Protein-Konjugat Impfstoffen durch Ultrafiltration mit Ammoniumsulfat-Lösungen

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE69934434T Expired - Lifetime DE69934434T2 (de) 1998-12-29 1999-12-16 Reinigung von polysaccharid-protein-konjugat impfstoffen durch ultrafiltration mit ammoniumsulfat-lösungen
DE69943169T Expired - Lifetime DE69943169D1 (de) 1998-12-29 1999-12-16 Reinigung von Polysaccharid-Protein-Konjugat Impfstoffen durch Ultrafiltration mit Ammoniumsulfat-Lösungen

Country Status (12)

Country Link
US (1) US6146902A (de)
EP (3) EP1762245B1 (de)
AT (2) ATE496633T1 (de)
AU (1) AU2367500A (de)
CA (2) CA2358022C (de)
CY (3) CY1105985T1 (de)
DE (3) DE69934434T2 (de)
DK (2) DK1762245T3 (de)
ES (2) ES2278551T3 (de)
HK (1) HK1106999A1 (de)
PT (2) PT1762245E (de)
WO (1) WO2000038711A2 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248334B1 (en) * 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
CZ20024224A3 (cs) * 2000-06-29 2003-05-14 Glaxosmithkline Biologicals S. A. Farmaceutický prostředek
AU2441402A (en) * 2000-10-18 2002-04-29 Clarity Technologies Inc Method and device for diluting a fluid and detecting analytes within a diluted fluid
HU230490B1 (hu) 2001-01-23 2016-08-29 Sanofi Pasteur Inc. Multivalens, meningokokkusz-eredetű poliszaccharid és fehérje konjugátumát tartalmazó vakcina
PT1373491E (pt) 2001-04-04 2016-03-31 Dsm Ip Assets Bv Lactase purificada
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA2514328C (en) * 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
JP2007516219A (ja) 2003-05-07 2007-06-21 アヴェンティス パストゥール インコーポレイテッド 髄膜炎菌ワクチン接種に対する免疫原性の増強の方法
CA2524860C (en) 2003-05-07 2016-09-13 Aventis Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
US20070020293A1 (en) * 2003-06-23 2007-01-25 Michon Francis J Vaccines against group neisseria meningitidis and meningococcal combinations thereof
WO2005000345A2 (en) 2003-06-23 2005-01-06 Aventis Pasteur, Inc. Immunization method against neisseria meningitidis serogroups a and c
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1670506B1 (de) 2003-10-02 2012-11-21 Novartis AG Flüssige vakzine für multiple meningokokken-serogruppen
JP2007519746A (ja) * 2004-01-29 2007-07-19 バイオシネクサス インコーポレーティッド ワクチン調製におけるアミノ−オキシ官能基の使用
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
WO2006026689A2 (en) * 2004-08-30 2006-03-09 Sanofi Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
KR20070095868A (ko) * 2004-09-21 2007-10-01 사노피 파스퇴르 인크 다가 수막구균 유도체화된 다당류-단백질 접합체 및 백신
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
PT1896065E (pt) 2005-06-27 2011-08-31 Glaxosmithkline Biolog Sa Processo para a preparação de vacinas
GB0513852D0 (en) * 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2007229449A1 (en) * 2006-03-22 2007-10-04 Novartis Ag Regimens for immunisation with meningococcal conjugates
US10828361B2 (en) * 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) * 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
WO2008028957A2 (en) 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Vaccine
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
MY150927A (en) * 2007-03-23 2014-03-14 Wyeth Corp Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides
EA201490303A1 (ru) 2007-05-02 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
PT2349520T (pt) 2008-10-27 2016-08-16 Glaxosmithkline Biologicals Sa Método de purificação para hidrato de carbono de estreptococos grupo a
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
SI2385981T1 (sl) 2008-12-18 2019-11-29 Wyeth Llc Postopek za nadzorovanje molekulske mase polisaharida streptococcus pneumoniae z uporabo ogljika
KR20110091546A (ko) * 2008-12-18 2011-08-11 와이어쓰 엘엘씨 스트렙토코커스 뉴모니에 혈청형 19ａ 폴리사카라이드 분자량을 조절하는 방법
EP3461496B1 (de) 2009-06-22 2023-08-23 Wyeth LLC Zusammensetzungen und verfahren zur herstellung von staphylococcus aureus serotyp-5 und 8-kapselpolysaccharid-konjugat-immunogenzusammensetzungen
JP5395264B2 (ja) 2009-06-22 2014-01-22 ワイス・エルエルシー 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）抗原の免疫原性組成物
US8647621B2 (en) 2009-07-27 2014-02-11 Fina Biosolutions, Llc Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
ES2812523T3 (es) 2009-09-30 2021-03-17 Glaxosmithkline Biologicals Sa Conjugación de polisacáridos capsulares de Staphylococcus aureus de tipo 5 y de tipo 8
MX2012004851A (es) 2009-10-30 2012-05-22 Novartis Ag Purificacion de sacaridos capsulares de staphylococcus aureus tipo 5 y tipo 8.
US8105843B2 (en) * 2009-11-04 2012-01-31 Buchanan Thomas M Methods and devices to enhance sensitivity and evaluate sample adequacy and reagent reactivity in rapid lateral flow immunoassays
EP2513056B1 (de) 2009-12-17 2022-05-04 Serum Institute of India Pvt. Ltd. Chemische reagenzien zur aktivierung von polysacchariden bei der herstellung von konjugatimpfstoffen
ES2707778T3 (es) 2009-12-30 2019-04-05 Glaxosmithkline Biologicals Sa Inmunógenos polisacáridos conjugados con proteínas portadoras de E. coli
ES2743156T3 (es) 2010-04-23 2020-02-18 Serum Institute Of India Pvt Ltd Método simple para eliminación simultánea de múltiples impurezas a partir de sobrenadantes de cultivo a niveles ultrabajos
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
TR201909110T4 (tr) 2011-09-14 2019-07-22 Glaxosmithkline Biologicals Sa Sakarit-protein glikokonjugatları yapmaya yönelik yöntemler.
US20140234360A1 (en) 2011-09-30 2014-08-21 The United States of America, as represented by the Secretary, Dept.of Health and Human Services Influenza vaccine
US9493517B2 (en) 2011-11-07 2016-11-15 Glaxosmithkline Biologicals Sa Conjugates comprising an antigen and a carrier molecule
MX2014014067A (es) 2012-05-22 2015-02-04 Novartis Ag Conjugado de serogrupo x de meningococo.
MX2015004171A (es) 2012-10-02 2015-10-22 Glaxosmithkline Biolog Sa Conjugados de sacaridos no lineales.
KR20150073943A (ko) 2012-10-03 2015-07-01 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
CN104387491B (zh) * 2014-11-25 2017-12-05 中国医学科学院医学生物学研究所 一种b型流感嗜血杆菌荚膜多糖的制备方法
EP3439704A1 (de) 2016-04-05 2019-02-13 GSK Vaccines S.r.l. Immunogene zusammensetzungen
EP4309670A3 (de) 2016-09-02 2024-07-17 Sanofi Pasteur, Inc. Neisseria-meningitidis-impfstoff
EP4070815A1 (de) 2016-10-03 2022-10-12 The U.S.A. as represented by the Secretary, Department of Health and Human Services Hiv-1-env-fusionspeptid-immunogene und deren verwendung
US11202824B2 (en) 2016-10-31 2021-12-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide fragments from filoviruses and their uses
US20210108002A1 (en) 2016-12-06 2021-04-15 Glaxosmithkline Biologicals Sa Purification Process For Capsular Polysaccharide
WO2018144438A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
KR20200051004A (ko) 2017-09-07 2020-05-12 머크 샤프 앤드 돔 코포레이션 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도
CN111683678B (zh) 2017-12-06 2024-01-26 默沙东有限责任公司 包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法
US11896656B2 (en) 2018-04-30 2024-02-13 Merck Sharp & Dohme Llc Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
CN112074293A (zh) 2018-04-30 2020-12-11 默沙东公司 生产肺炎链球菌荚膜多糖载体蛋白缀合物的方法
WO2020061564A1 (en) 2018-09-23 2020-03-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 env fusion peptide nanoparticle carrier conjugates and their use
SG11202106541WA (en) 2018-12-19 2021-07-29 Merck Sharp & Dohme Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CN113966234A (zh) 2019-05-10 2022-01-21 葛兰素史克生物有限公司 缀合物的产生
JP2023529925A (ja) 2020-06-12 2023-07-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ナノ粒子ワクチンを使用する細菌免疫化
JP2023548935A (ja) 2020-11-13 2023-11-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規担体及びコンジュゲーション法
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
WO2022182388A1 (en) * 2021-02-26 2022-09-01 The Penn State Research Foundation Separation apparatus and method
WO2023111826A1 (en) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Bacterial immunization using qbeta hairpin nanoparticle constructs
WO2023200704A1 (en) 2022-04-11 2023-10-19 Sanofi Pasteur Inc. Protein-saccharide conjugation with sodium cyanoborohydride

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4456691A (en) * 1983-02-28 1984-06-26 Suad Stark Antigen for PCB, antibody raised by same, and method of making same
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US4780409A (en) * 1985-05-02 1988-10-25 Genetic Systems Corporation Thermally induced phase separation immunoassay
JPH0643336B2 (ja) * 1988-06-30 1994-06-08 呉羽化学工業株式会社 血管増殖抑制剤
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
AU1140495A (en) * 1994-01-27 1995-08-03 Bristol-Myers Squibb Company Method for preparing thioether conjugates
SE9601158D0 (sv) * 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
FR2748476B1 (fr) * 1996-05-07 1998-08-14 Pf Medicament Complexe immunogene, son utilisation, son procede de preparation et vaccin le contenant
US6248334B1 (en) * 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules

Also Published As

Publication number Publication date
CY2200152T2 (el) 2010-07-28
DE69943169D1 (de) 2011-03-10
CY1111375T1 (el) 2015-08-05
EP1140156B1 (de) 2006-12-13
ES2277462T3 (es) 2007-07-01
EP1762245A2 (de) 2007-03-14
DE69934434D1 (de) 2007-01-25
WO2000038711A3 (en) 2000-10-19
DE69934434T2 (de) 2008-01-03
EP2292261A1 (de) 2011-03-09
WO2000038711A2 (en) 2000-07-06
EP1762245B1 (de) 2011-01-26
CA2358022A1 (en) 2000-07-06
AU2367500A (en) 2000-07-31
CA2358022C (en) 2008-03-11
CY1105985T1 (el) 2011-04-06
DK1762245T3 (da) 2011-04-04
ES2278551T3 (es) 2011-04-11
ES2278551T1 (es) 2007-08-16
CA2621097A1 (en) 2000-07-06
ATE496633T1 (de) 2011-02-15
DK1140156T3 (da) 2007-03-26
PT1140156E (pt) 2007-02-28
EP1140156A2 (de) 2001-10-10
US6146902A (en) 2000-11-14
HK1106999A1 (en) 2008-03-28
EP1762245A3 (de) 2007-04-25
PT1762245E (pt) 2011-05-02
ATE347906T1 (de) 2007-01-15

Similar Documents

Publication Publication Date Title
DE06025470T1 (de) Reinigung von Polysaccharid-Protein-Konjugat Impfstoffen durch Ultrafiltration mit Ammoniumsulfat-Lösungen
DE69827127T2 (de) Mehrwertige impstoffzusammensetzung mit gemischten trägern
DE69612198T3 (de) Eine Impfstoffzusammensetzung, bestehend aus einem Haemophilus influenzae B Polysaccharid Antigen-Konjugat adsorbiert an Aluminiumphosphat
DE60210456T2 (de) Solubilisierung von capsulären Polysacchariden
JP2006512402A5 (de)
US6891037B1 (en) Method for the isolation of polysaccharides
EP0319862A3 (de) Biocompatible Dialysemembran aus Cellulose mit erhöhter Beta-2-Microglobulinadsorption
DE69231663T2 (de) Polysaccharid-protein-konjugate
DE60315827T3 (de) Verbesserte polysaccharid- und glykokonjugat-vakzine
DE3881439D1 (de) Tetrahydropyridin-oxime, verfahren zu ihrer herstellung und ihre verwendung als cholinergische mittel.
CH690490C2 (de) Anthracyclinglycosidlösung.
DE3024282A1 (de) Vakzinierende glycopeptid-antigenfraktion mit grosser immunisierungsfaehigkeit, isoliert aus kulturen pathogener keime, verfahren zur isolierung dieser fraktion und diese enthaltende vakzinen
DE69227984T2 (de) Impfstoff, der eine Untereinheit des menschlichen Transferrin-Rezeptors von Neisseria meningitidis enthält
Charoenpanich et al. Effect of first and subsequent use of hemodialyzers on patient well‐being: the rise and fall of a syndrome associated with new dialyzer use
CN105669873B (zh) 不同血清型肺炎链球菌荚膜多糖的水解方法
CH455146A (de) Verfahren zur Herstellung von Diphtherie-Toxoiden
JP2009519294A (ja) マクロライド系抗生物質を精製する方法
CH514497A (de) Füllmaterial aus Fasern für Decken, Kissen, Polstermöbel und dergleichen sowie Verfahren und Vorrichtung zur Herstellung des Füllmaterials
GB1496671A (en) Anti-cancer-active sour milk fraction
DE69729800T2 (de) Bordetella pertussis aussermembran proteinfragmente enthaltende impfstoffzusammensetzung
EP1407942A3 (de) Gassack für ein Fahrzeuginsassen-Rückhaltesystem und Verfahren zu dessen Herstellung
AU2008201363A1 (en) Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
Leakey et al. Response: Fossil Hominid Taxonomy
AT42237B (de) Verfahren zur Darstellung von Antikokkenseras.
RU2020133440A (ru) КАПСУЛЬНЫЙ ПОЛИСАХАРИД Streptococcus pneumoniae И ЕГО ИММУНОГЕННЫЙ КОНЪЮГАТ